# Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

> **NCT06279351** · PHASE2 · RECRUITING · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 96 (estimated)

## Conditions studied

- Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

## Interventions

- **DRUG:** Thalidomide+cetuximab+FOLFOX/FOLFIRI

## Key facts

- **NCT ID:** NCT06279351
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-11
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279351, "Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06279351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*